{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:36Z","timestamp":1793401176555,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.gastro.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T13:20:59Z","timestamp":1460380859000},"page":"70-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":494,"title":["Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in\u00a0Interferon-Free Regimens"],"prefix":"10.1053","volume":"151","author":[{"given":"Jean-Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.04.003_bib1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.04.003_bib2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2015.01.002","article-title":"Hepatitis C treatment: the data flood goes on. An update from The Liver Meeting 2014","volume":"148","author":"Pawlotsky","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.04.003_bib3","first-page":"261","article-title":"Hepatitis C virus population dynamics during infection","volume":"299","author":"Pawlotsky","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1053\/j.gastro.2016.04.003_bib4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in\u00a0vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1053\/j.gastro.2016.04.003_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0034-1371007","article-title":"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development","volume":"34","author":"Pawlotsky","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2016.04.003_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state-of-the-art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2012.02.027","article-title":"New virologic tools for management of chronic hepatitis B and C","volume":"142","author":"Chevaliez","year":"2012","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib9","first-page":"322A","article-title":"The emergence of NS5B resistant associated variant S282T after sofosbuvir-based treatment (abstr)","volume":"62","author":"Gane","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib10","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2016.04.003_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib12","first-page":"254A","article-title":"Prevalence of pretreatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF (abstr)","volume":"62","author":"Zeuzem","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib15","first-page":"563A","article-title":"Resistance analysis of treatment-na\u00efve and DAA-experienced genotype 1 patients with and without cirrhosis who received short-duration treatment with sofosbuvir\/GS-5816\u00a0+ GS-9857 (abstr)","volume":"62","author":"Gane","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib16","unstructured":"Sulkowski M, Krishnan P, Tripathi R, et\u00a0al. Effect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2016; February 22-25, 2016; Boston, MA."},{"issue":"suppl","key":"10.1053\/j.gastro.2016.04.003_bib17","first-page":"1128A","article-title":"Baseline and post-baseline resistance analyses of Phase 2\/3 studies of ledipasvir\/sofosbuvir\u00a0+\/- RBV (abstr)","volume":"60","author":"Sarrazin","year":"2014","journal-title":"Hepatology"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib18","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvir\u00a0+\/- RBV (abstr)","volume":"62","author":"Sarrazin","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib19","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib20","first-page":"560A","volume":"62","author":"McPhee","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.04.003_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28467","article-title":"Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a Phase 3, randomized study","author":"Kwo","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib24","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","article-title":"High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms","volume":"32","author":"McPhee","year":"2015","journal-title":"Adv Ther"},{"key":"10.1053\/j.gastro.2016.04.003_bib26","article-title":"Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis","author":"Kao","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2016.04.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib28","first-page":"1393A","article-title":"Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection (abstr)","volume":"62","author":"Jacobson","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib29","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.04.003_bib30","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.04.003_bib31","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib32","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S0168-8278(15)30070-2","article-title":"Ledipasvir\/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection (abstr)","volume":"62","author":"Abergel","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib33","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks (abstr)","volume":"62","author":"Lawitz","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib34","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens (abstr)","volume":"62","author":"Krishnan","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib35","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","article-title":"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir\/ritonavir","volume":"59","author":"Schnell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2016.04.003_bib36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.04.003_bib38","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized Phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib39","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.04.003_bib40","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib41","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31094-1","article-title":"Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir\/elbasvir\u00a0+\/- ribavirin: the C-WORTHY study (abstr)","volume":"62","author":"Black","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE","volume":"62","author":"Buti","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2016.04.003_bib43","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib44","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S0168-8278(15)30015-5","article-title":"Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT Part A) (abstr)","volume":"62","author":"Jacobson","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib45","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30013-1","article-title":"C-SWIFT: grazoprevir\/elbasvir\u00a0+ sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 and 12 weeks (abstr)","volume":"62","author":"Poordad","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib46","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(15)30073-8","article-title":"Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir (abstr)","volume":"62","author":"Dvory-Sobol","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2016.04.003_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.10.010","article-title":"Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C","volume":"113","author":"Howe","year":"2015","journal-title":"Antiviral Res"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib49","first-page":"763A","article-title":"Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen (abstr)","volume":"62","author":"H\u00e9zode","year":"2015","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.04.003_bib50","first-page":"1392A","article-title":"Retreatment of HCV genotype 1 DAA-failures with ombitasvir\/paritaprevir\/r, dasabuvir, and sofosbuvir (abstr)","volume":"62","author":"Poordad","year":"2015","journal-title":"Hepatology"},{"issue":"suppl 2","key":"10.1053\/j.gastro.2016.04.003_bib51","first-page":"1386A","article-title":"C-SWIFT Retreatment (Part B): 12 weeks of elbasvir\/grazoprevir with sofosbuvir and ribavirin successfully treated GT1-infected subjects who failed short-duration all-oral therapy (abstr)","volume":"62","author":"Lawitz","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib52","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.3390\/v7122941","article-title":"Virologic tools for HCV drug resistance testing","volume":"7","author":"Fourati","year":"2015","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2016.04.003_bib53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2016.04.003_bib54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.04.003_bib55","unstructured":"Highlights of prescribing information. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf."}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516300555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516300555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T08:52:18Z","timestamp":1536828738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516300555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0016508516300555"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.04.003","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in\u00a0Interferon-Free Regimens","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}